A passive 6.6% stake from a large custodian/asset manager is routine and does not signal an activist campaign. Monitor for any future 13D conversion or additional accumulation, but the passive certification and State Street's typical role as an index/ETF manager make that unlikely.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $64.14entry
- T+1 · 6d ago +1.20%α −0.12% · $64.91
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp disclosed a 6.6% passive stake in PTC Therapeutics via a Schedule 13G filed November 10, 2026, holding 5,512,555 shares as of September 30, 2026. This is a new 13G filing (no prior 13G from State Street on file), indicating the custodian bank crossed the 5% threshold through its asset management subsidiaries. The passive certification and absence of prior filings suggest routine portfolio accumulation, not activist intent.
Key Financial Metrics
Key Facts
- State Street Corp filed a new Schedule 13G disclosing beneficial ownership of 5,512,555 shares of PTC Therapeutics common stock
- The stake represents 6.6% of shares outstanding as of September 30, 2026
- State Street certifies passive intent under Rule 13d-1(b), with no purpose of changing or influencing control
- The filing is new (not an amendment); no prior 13G from State Street for PTCT appears in the cross-filing context
- State Street's subsidiaries holding shares include SSGA Funds Management, State Street Global Advisors entities, and State Street Global Advisors Trust Company
Financial Impact
6.6% stake valued at approximately $363M based on $5.5B market cap
Risk Factors
- No material risks identified from this passive stake filing
- State Street may reduce the position without further disclosure if it falls below 5%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000707 |
| Document: 0000093751-26-000707-index.html | 0000093751-26-000707 |
| Document: 0000093751-26-000707.txt | 0000093751-26-000707 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers